Activity of ETX0462 toward Some Burkholderia spp

Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment options for infections. Here, a novel diazabicyclooctane, ETX0462, was evaluated for activity against Bcc and . . Ninety-eight percent of the iso...

Full description

Saved in:
Bibliographic Details
Published inAntimicrobial agents and chemotherapy Vol. 67; no. 1; p. e0135222
Main Authors Zeiser, Elise T, Becka, Scott A, LiPuma, John J, Papp-Wallace, Krisztina M
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 24.01.2023
Subjects
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Antimicrobial Chemotherapy
Burkholderia
Burkholderia cepacia complex
Burkholderia Infections - drug therapy
Ceftazidime - therapeutic use
Humans
Susceptibility
Trimethoprim, Sulfamethoxazole Drug Combination - pharmacology
Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use
ETX0462
beta-lactamase
Burkholderia
penicillin binding protein
beta-lactam
diazabicyclooctane
Online AccessGet full text

Cover

More Information
Summary:Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are opportunistic human pathogens that are inherently multidrug resistant, limiting treatment options for infections. Here, a novel diazabicyclooctane, ETX0462, was evaluated for activity against Bcc and . . Ninety-eight percent of the isolates examined in this study were susceptible. ETX0462 was found to demonstrate activity superior to that of currently available treatment options (e.g., trimethoprim-sulfamethoxazole and ceftazidime).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
The authors declare a conflict of interest. Entasis Therapeutics provided funding as a research grant to K.M.P.-W. to conduct this study.
ISSN:0066-4804
1098-6596
DOI:10.1128/aac.01352-22